News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Amgen Shares Soar As Roche Anti-Anemia Drug CERA Delayed
February 1, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Amgen Inc. stock climbed Wednesday after Roche Holding AG of Switzerland delayed a plan to submit its anemia drug for U.S. regulatory approval, further opening the opportunity for Amgen's drug, Aranesp.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Amgen
Roche
MORE ON THIS TOPIC
GLP-1
FDA Asks Novo, Lilly To Remove Suicide Warnings From GLP-1 Weight Loss Products
January 14, 2026
·
1 min read
·
Tristan Manalac
Podcast
Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy
January 14, 2026
·
2 min read
·
Heather McKenzie
Approvals
Sentynl, Fortress Bounce Back With FDA Approval for Rare Pediatric Disease
January 13, 2026
·
2 min read
·
Tristan Manalac
Regulatory
FDA Carves Out Manufacturing Exemptions for CGTs To Accelerate Development
January 12, 2026
·
2 min read
·
Tristan Manalac
